Oncology

  • 7 April 2020
    News

    Immunomedics stops Phase III breast cancer study early

    Biopharmaceutical company Immunomedics has stopped the confirmatory Phase III ASCENT clinical trial of sacituzumab govitecan early after obtaining encouraging efficacy data in metastatic triple-negative breast cancer (mTNBC) patients.

Close
Close
Close

Go Top